NCT04582045 is a clinical trial of silver impregnated dressing in D001458, sponsored by HealthPartners Institute.

Who is sponsoring NCT04582045?

NCT04582045 is sponsored by HealthPartners Institute.

What drugs are being tested in NCT04582045?

Interventions in NCT04582045: silver impregnated dressing.

What condition does NCT04582045 study?

NCT04582045 studies D001458, D011247.

Is NCT04582045 still recruiting?

NCT04582045 is currently completed. Last updated 19 January 2023.

Are results published for NCT04582045?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-01-19 · How we verify

NCT04582045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Prophylactic Negative Pressure Versus Silver Impregnated Silicone Bandage on C-Section Infection Rates

Completed Results posted Last updated 19 January 2023

What this trial tests

trial testing silver impregnated dressing in D001458 in 1,064 participants. Completed in 15 June 2021.

Timeline

1 March 2019

Primary endpoint
1 March 2021

15 June 2021

Quick facts

Lead sponsor	HealthPartners Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,064
Start date	1 March 2019
Primary completion	1 March 2021
Estimated completion	15 June 2021
Sites	1 location across United States

Drugs / interventions tested

silver impregnated dressing

Conditions studied

D001458 — all drugs for D001458 →
D011247 — all drugs for D011247 →

Sponsor

HealthPartners Institute

Who can join

Adults 18 to 55, female only, with D001458 or D011247. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Infection Rate Primary · 30 days from surgery

rate of post operative infection

Group	Value	95% CI
Low Risk, Silver Impregnated	17
Low Risk, Border Bandage	18
High-risk, Silver Impregnated	5
High-risk, Wound Vacuum	5

Adverse events — posted to ClinicalTrials.gov

Time frame: 180-days post delivery (6-months). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Low Risk, Silver Impregnated

Serious: 24/446 (5%)

Deaths: 0/446

Low Risk, Border Bandage

Serious: 13/440 (3%)

Deaths: 0/440

High-risk, Silver Impregnated

Serious: 5/95 (5%)

Deaths: 0/95

High-risk, Wound Vacuum

Serious: 1/83 (1%)

Deaths: 0/83

Serious adverse events (1 terms)

Reaction	System	Low Risk, Silver Impregnated	Low Risk, Border Bandage	High-risk, Silver Impregna…	High-risk, Wound Vacuum
POST-PARTUM HOSPITALIZATION (6-months)	Reproductive system and breast disorders	—	—	—	—

Other adverse events (1 terms — click to expand)

Reaction	System	Low Risk, Silver Impregnated	Low Risk, Border Bandage	High-risk, Silver Impregna…	High-risk, Wound Vacuum
Superficial Wound Infections	Skin and subcutaneous tissue disorders	—	—	—	—

Most-reported serious reactions: POST-PARTUM HOSPITALIZATION (6-months).

Data from ClinicalTrials.gov NCT04582045 adverse events section.

Sponsor's own description

Effect of Prophylactic Negative Pressure versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Role of Silver and Silver-Based Products in Wound Management: A Review of Advances and Current Landscape.
Du Y, Lu J, Guo X, Xia Z, et al · · 2026 · PMID 41590795 · DOI 10.3390/jfb17010027

Verify or expand the search:

Other HealthPartners Institute trials

Trials by the same sponsor.

NCT07127133 — An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzhei · NA · not yet recruiting
NCT07354919 — Axelopran in Advanced Cancers · Phase 2 · not yet recruiting
NCT06434038 — Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age · Phase 1 · withdrawn
NCT06914726 — Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes · NA · enrolling by invitation
NCT06999330 — TMS in Anxiety-Parkinson's Disease · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04582045 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HealthPartners Institute
Last refreshed: 19 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04582045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing